Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases.
Animals
Antineoplastic Agents
/ administration & dosage
Blood-Brain Barrier
/ drug effects
Brain Neoplasms
/ diagnostic imaging
Breast Neoplasms
/ diagnostic imaging
Cell Line, Tumor
Claudin-5
/ genetics
Docetaxel
/ administration & dosage
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Magnetic Resonance Imaging
Mice
Microscopy, Electron
Sequence Analysis, RNA
Tubulin
/ genetics
Xenograft Model Antitumor Assays
BBB
Brain metastasis
Breast cancer
Docetaxel
TEER
Taxane
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
29 Oct 2019
29 Oct 2019
Historique:
received:
21
07
2019
accepted:
23
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
25
3
2020
Statut:
epublish
Résumé
Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40% is due to more effective treatments of extracerebral sites with improved prognosis and increasing use of MRI in diagnostics. A frequently administered, potent chemotherapeutic group of drugs for BC treatment are taxanes usually used in the adjuvant and metastatic setting, which, however, have been suspected to be associated with a higher incidence of BM. The aim of our study was to experimentally analyze the impact of the taxane docetaxel (DTX) on brain metastasis formation, and to elucidate the underlying molecular mechanism. A monocentric patient cohort was analyzed to determine the association of taxane treatment and BM formation. To identify the specific impact of DTX, a murine brain metastatic model upon intracardial injection of breast cancer cells was conducted. To approach the functional mechanism, dynamic contrast-enhanced MRI and electron microscopy of mice as well as in-vitro transendothelial electrical resistance (TEER) and tracer permeability assays using brain endothelial cells (EC) were carried out. PCR-based, immunohistochemical and immunoblotting analyses with additional RNA sequencing of murine and human ECs were performed to explore the molecular mechanisms by DTX treatment. Taxane treatment was associated with an increased rate of BM formation in the patient cohort and the murine metastatic model. Functional studies did not show unequivocal alterations of blood-brain barrier properties upon DTX treatment in-vivo, but in-vitro assays revealed a temporary DTX-related barrier disruption. We found disturbance of tubulin structure and upregulation of tight junction marker claudin-5 in ECs. Furthermore, upregulation of several members of the tubulin family and downregulation of tetraspanin-2 in both, murine and human ECs, was induced. In summary, a higher incidence of BM was associated with prior taxane treatment in both a patient cohort and a murine mouse model. We could identify tubulin family members and tetraspanin-2 as potential contributors for the destabilization of the blood-brain barrier. Further analyses are needed to decipher the exact role of those alterations on tumor metastatic processes in the brain.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40% is due to more effective treatments of extracerebral sites with improved prognosis and increasing use of MRI in diagnostics. A frequently administered, potent chemotherapeutic group of drugs for BC treatment are taxanes usually used in the adjuvant and metastatic setting, which, however, have been suspected to be associated with a higher incidence of BM. The aim of our study was to experimentally analyze the impact of the taxane docetaxel (DTX) on brain metastasis formation, and to elucidate the underlying molecular mechanism.
METHODS
METHODS
A monocentric patient cohort was analyzed to determine the association of taxane treatment and BM formation. To identify the specific impact of DTX, a murine brain metastatic model upon intracardial injection of breast cancer cells was conducted. To approach the functional mechanism, dynamic contrast-enhanced MRI and electron microscopy of mice as well as in-vitro transendothelial electrical resistance (TEER) and tracer permeability assays using brain endothelial cells (EC) were carried out. PCR-based, immunohistochemical and immunoblotting analyses with additional RNA sequencing of murine and human ECs were performed to explore the molecular mechanisms by DTX treatment.
RESULTS
RESULTS
Taxane treatment was associated with an increased rate of BM formation in the patient cohort and the murine metastatic model. Functional studies did not show unequivocal alterations of blood-brain barrier properties upon DTX treatment in-vivo, but in-vitro assays revealed a temporary DTX-related barrier disruption. We found disturbance of tubulin structure and upregulation of tight junction marker claudin-5 in ECs. Furthermore, upregulation of several members of the tubulin family and downregulation of tetraspanin-2 in both, murine and human ECs, was induced.
CONCLUSION
CONCLUSIONS
In summary, a higher incidence of BM was associated with prior taxane treatment in both a patient cohort and a murine mouse model. We could identify tubulin family members and tetraspanin-2 as potential contributors for the destabilization of the blood-brain barrier. Further analyses are needed to decipher the exact role of those alterations on tumor metastatic processes in the brain.
Identifiants
pubmed: 31665089
doi: 10.1186/s13046-019-1427-1
pii: 10.1186/s13046-019-1427-1
pmc: PMC6819416
doi:
Substances chimiques
Antineoplastic Agents
0
CLDN5 protein, human
0
Claudin-5
0
Tubulin
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
434Subventions
Organisme : Fonds National de la Recherche Luxembourg
ID : PEARL P16/BM/11192868
Références
J Cereb Blood Flow Metab. 2016 Jul;36(7):1281-94
pubmed: 26661166
Nat Med. 2010 Jan;16(1):116-22
pubmed: 20023634
Am J Pathol. 2010 Jun;176(6):2958-71
pubmed: 20382702
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a006550
pubmed: 22951441
Methods Mol Biol. 2014;1135:415-37
pubmed: 24510883
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Cancer. 2006 Jan 15;118(2):317-25
pubmed: 16080190
PLoS One. 2011;6(6):e20758
pubmed: 21674054
Cancer Res. 2007 May 1;67(9):4138-48
pubmed: 17483324
Acta Neuropathol. 2016 May;131(5):753-73
pubmed: 26932603
Mol Cancer Ther. 2014 Sep;13(9):2170-83
pubmed: 24980948
Cell Commun Signal. 2008 Dec 04;6:10
pubmed: 19055814
Neuron. 2010 Jul 29;67(2):181-98
pubmed: 20670828
Cancer. 1995 Jul 15;76(2):232-6
pubmed: 8625097
Oncogene. 2008 Jan 31;27(6):831-8
pubmed: 17637738
J Cereb Blood Flow Metab. 2010 Sep;30(9):1625-36
pubmed: 20234382
Ann Oncol. 2008 Nov;19(11):1837-41
pubmed: 18562328
PLoS One. 2016 Mar 09;11(3):e0151155
pubmed: 26958843
BMC Cell Biol. 2006 Mar 01;7:12
pubmed: 16509970
Am J Pathol. 2005 Oct;167(4):913-20
pubmed: 16192626
Exp Hematol Oncol. 2015 Nov 24;4:33
pubmed: 26605131
Biochem Soc Trans. 2017 Apr 15;45(2):465-475
pubmed: 28408487
Cancer Res. 1986 Oct;46(10):5172-8
pubmed: 3756871
Int J Mol Sci. 2014 May 28;15(6):9519-30
pubmed: 24879524
Curr Cancer Drug Targets. 2003 Jun;3(3):193-203
pubmed: 12769688
PLoS One. 2013 Aug 05;8(8):e70233
pubmed: 23940549
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103
pubmed: 18664652
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Clin Cancer Res. 2010 Dec 1;16(23):5664-78
pubmed: 20829328
Brain Pathol. 2015 Jul;25(4):491-504
pubmed: 25175718
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
FASEB J. 2004 Dec;18(15):1879-90
pubmed: 15576491
Acta Neuropathol. 2012 Feb;123(2):205-22
pubmed: 22212630
J Cereb Blood Flow Metab. 2016 May;36(5):862-90
pubmed: 26868179
J Clin Oncol. 1989 Sep;7(9):1239-51
pubmed: 2549203
Cancer. 2017 Jun 1;123(S11):2163-2175
pubmed: 28543697
J Cell Physiol. 2005 Sep;204(3):934-47
pubmed: 15828024
Mol Biol Cell. 2005 Sep;16(9):3919-36
pubmed: 15958494
Sci Rep. 2016 Jun 06;6:27382
pubmed: 27263528
Science. 1977 Aug 26;197(4306):893-5
pubmed: 887927
Breast Cancer Res. 2016 Jan 19;18(1):8
pubmed: 26781299
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Free Radic Res. 2009 Apr;43(4):348-64
pubmed: 19241241
Cancer Treat Rev. 2000 Dec;26(6):449-62
pubmed: 11139374
Mol Cancer Ther. 2002 Nov;1(13):1191-200
pubmed: 12479700
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Nature. 1979 Feb 22;277(5698):665-7
pubmed: 423966
J Neurol Sci. 1995 Dec;134(1-2):26-32
pubmed: 8747839
Drug Des Devel Ther. 2012;6:371-84
pubmed: 23251087
Am J Physiol Cell Physiol. 2014 Aug 1;307(3):C245-54
pubmed: 24920678
Int J Mol Sci. 2013 Jan 11;14(1):1383-411
pubmed: 23344048
PLoS One. 2011;6(12):e28881
pubmed: 22216132
Cell Mol Neurobiol. 2005 Feb;25(1):59-127
pubmed: 15962509
Cancer. 2006 Aug 15;107(4):696-704
pubmed: 16826579
Biol Cell. 2015 Oct;107(10):342-71
pubmed: 26032862
Virchows Arch. 2017 Mar;470(3):275-283
pubmed: 28101678
J Mol Med (Berl). 2015 Nov;93(11):1213-20
pubmed: 26489608
Cancer. 2006 Jun 1;106(11):2337-44
pubmed: 16649217
FASEB J. 2005 Aug;19(10):1299-301
pubmed: 15946994
Ann Oncol. 2001 Mar;12(3):353-6
pubmed: 11332148
Cancer. 1982 Feb 15;49(4):651-4
pubmed: 7055779
Cancer Res. 2006 Aug 15;66(16):8192-9
pubmed: 16912198
Curr Neurovasc Res. 2008 Feb;5(1):71-81
pubmed: 18289024